Scarica l'app Stockscreener
0.9999
1.97%
-0.0201
Dopo l'orario di chiusura:
1.00
0.000100
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ALZN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.02
Aprire:
$1.01
Volume 24 ore:
93,629
Relative Volume:
0.68
Capitalizzazione di mercato:
$3.80M
Reddito:
-
Utile/perdita netta:
$-7.04M
Rapporto P/E:
-0.2284
EPS:
-4.3784
Flusso di cassa netto:
$-6.17M
1 W Prestazione:
-33.34%
1M Prestazione:
-50.25%
6M Prestazione:
-59.52%
1 anno Prestazione:
-89.32%
Intervallo 1D:
$0.98
$1.0299
Intervallo di 1 settimana:
$0.98
$1.44
Portata 52W:
$0.98
$9.45
Alzamend Neuro Inc Stock (ALZN) Company Profile
Nome
Alzamend Neuro Inc
Settore
Industria
Telefono
844-722-6333
Indirizzo
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA
Compare ALZN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
0.9999 | 3.80M | 0 | -7.04M | -6.17M | -4.3784 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-01 | Iniziato | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Borsa (ALZN) Ultime notizie
ALZN Stock Price, Quote & Chart | ALZAMEND NEURO INC (NASDAQ:ALZN) - ChartMill
Hedge Fund Bets: Can Alzamend Neuro Inc disrupt its industryChart Signals & Consistent Income Trade Recommendations - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Alzamend Neuro in Freefall: A 22% Plunge Shatters $1.93 as Panic Sets In - Bitget
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - Investing News Network
Alzamend’s AL001 meets bioequivalence in phase 2 brain trial - Investing.com
Alzamend’s AL001 meets bioequivalence in phase 2 brain trial By Investing.com - Investing.com Canada
Across 26 brain regions, Alzamend’s lithium drug showed higher levels - Stock Titan
Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency - theglobeandmail.com
Alzamend Neuro, Inc. Receives Nasdaq Delisting Notice: SEC Form 8-K Filing March 2026 - Minichart
Alzamend Neuro Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] Alzamend Neuro, Inc. Reports Material Event - Stock Titan
Exit Recap: How sensitive is Alzamend Neuro Inc to inflationEarnings Performance Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Quarterly Recap: Will PAVM outperform during market rallies2026 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
Alzamend initiates phase II trial of AL001 in bipolar disorder By Investing.com - Investing.com South Africa
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - Investing News Network
Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital - marketscreener.com
Alzamend initiates phase II trial of AL001 in bipolar disorder - Investing.com
Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital - TradingView
Alzamend Neuro, Inc. Q3 2026 Financial Results and SEC 10-Q Filing Overview - Minichart
Alzamend Neuro 10-Q: $0.00M Revenue, $(0.58) EPS Q3; $(1.89) EPS YTD - TradingView
Alzamend Neuro (NASDAQ: ALZN) posts $5.9M loss and warns on going concern - Stock Titan
Alzamend Neuro Establishes ATM Equity Offering Agreement - The Globe and Mail
Is Alzamend Neuro Inc stock a hidden gemEarnings Growth Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stockSEC filing - marketscreener.com
Alzamend Neuro Launches $3 Million ATM Equity Program With Ascendiant Capital Markets - TradingView
Alzamend Neuro (ALZN) launches $3.0M at-the-market common stock offering - Stock Titan
Alzamend Neuro Inc expected to post a loss of $1.92 a shareEarnings Preview - TradingView
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
ALZN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALZN Should I Buy - Intellectia AI
Alzamend Neuro (ALZN) to Release Quarterly Earnings on Monday - Defense World
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Expands By 51.2% - Defense World
ALZN Technical Analysis & ETF Price Forecast - Intellectia AI
Reverse split and new equity plan in Alzamend Neuro (ALZN) 2026 proxy - Stock Titan
How risky is Alzamend Neuro Inc. stock now2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - mfd.ru
Can Alzamend Neuro Inc. stock hit record highs againMarket Activity Report & Verified Trade Idea Suggestions - mfd.ru
Is Alzamend Neuro Inc. benefiting from interest rate changesEarnings Overview Report & Daily Price Action Insights - mfd.ru
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Will Alzamend Neuro Inc. announce a stock splitJuly 2025 Chart Watch & Fast Momentum Entry Tips - mfd.ru
What’s the fair value of Alzamend Neuro Inc. stockQuarterly Earnings Summary & Reliable Entry Point Trade Alerts - mfd.ru
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why - Defense World
Earnings Update: What is Alzamend Neuro Incs TAM Total Addressable MarketJuly 2025 Earnings & Technical Pattern Recognition Alerts - baoquankhu1.vn
EPS Watch: What is Alzamend Neuro Incs TAM Total Addressable MarketJuly 2025 Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Community Health Systems Incs ROE strong enough2025 Biggest Moves & Real-Time Market Sentiment Reports - baoquankhu1.vn
Is Alzamend Neuro Inc. stock heavily shortedWeekly Profit Analysis & Daily Profit Maximizing Tips - bollywoodhelpline.com
Aug Sectors: Is Alzamend Neuro Inc stock heavily shortedJuly 2025 News Drivers & Weekly High Return Opportunities - baoquankhu1.vn
Bond Watch: Can Alzamend Neuro Inc stock beat market expectations this quarterQuarterly Growth Report & Capital Protection Trade Alerts - Bộ Nội Vụ
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell? - Defense World
Can Alzamend Neuro Inc. stock beat analyst upgradesJuly 2025 Outlook & Safe Entry Point Identification - ulpravda.ru
Alzamend Neuro Inc Azioni (ALZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):